Time To Buy Cempra?
This article was originally published in Scrip
You may also be interested in...
FDA schedules November advisory committee for Cempra's first-in-class antibiotic for community-acquired bacterial pneumonia.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.